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A commentary on
Toward a new focus in antibiotic and drug discovery from the Streptomyces arsenal
by Antoraz, S., Santamaría, R. I., Díaz, M., Sanz, D., and Rodríguez, H. (2015). Front. Microbiol.
6:461. doi: 10.3389/fmicb.2015.00461
Infectious diseases caused by bacteria, particularly those gaining drug-resistance, are among the top
causes of mortality in the world (Overbye and Barrett, 2005). The mechanisms of multidrug eﬄux
systems, enzymatic modification and inactivation of drug molecules have enabled the resistant
bacteria to reduce the potency of common antibiotics (van Hoek et al., 2011; Lin et al., 2015).
Thus, the discovery of new antimicrobials and expansion of utility of existing antibiotics by
overproduction or targeted modification is crucial to combat the ever-increasing antimicrobial
resistance (Dhakal et al., 2015; Lin et al., 2015).
Streptomyces is the major sources of natural products including effective antimicrobials
(Chaudhary et al., 2013). Antoraz et al. (2015) have summarized advances on drug discovery
from Streptomyces arsenal, illustrating different approaches for elicitation of antimicrobials by
nutritional and hormonal signals or production of useful antimicrobials by co-culture and in situ
culture technologies. The authors have flash-lighted on utility of different synthetic biological
and system biological based metabolic engineering techniques for harnessing the biosynthetic
capabilities of Streptomyces. It can give rise to superfluous possibilities for antibiotic discovery by
using these precise genetic engineering techniques.
Genome mining has revealed that Streptomyces can harbor numerous active or cryptic
biosynthetic gene clusters encoding for diverse compounds including novel antimicrobials
(Chaudhary et al., 2013). Fundamentally, identification of novel antimicrobials can be achieved
by high throughput screening techniques, either (a) compound specific screening or (b)
organism specific screening (Figure 1A). In the first approach, the structurally characterized
molecule is tested against different pathogenic organisms. In next approach, the pathogenic
organism is screened against different putative compounds and effects are assessed. Furthermore,
bioinformatics tools assisting on studies rendering to structure-activity relationships (SAR) or
quantitative structure activity relationship (QSAR) can assist in developing the effective drug
molecules from microbial resources.
Antoraz et al. (2015) indicated that the application of bioinformatics and “-omic” based
engineering have important contribution in drug discovery. The key focus of these technologies
is production and overproduction of important molecules or their structural/functional
diversification for pharmaceutical value. The precise knowledge of biochemistry of secondary
metabolites production supported with advanced system biological and integrated “-omic”
techniques provide rational strategies for production and overproduction of targeted compounds
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FIGURE 1 | Integrated approach for exploiting Streptomyces arsenal
to combat the antibiotic resistance. (A) Extensive screening strategies for
identifying lead antimicrobials: (a) Compound specific screening (b)
Pathogenic organism specific screening. (B) Production and overproduction
strategies. The knowledge of synthetic biology, integrated-omics (genomics,
proteomics, metabolomics, etc…) and system biology can be used for
developing efficient production host. The performance of host can be further
ameliorated with media optimization and fermentation technology for
optimum production. (C) Compound modification and diversification
strategies. By using knowledge of synthetic chemistry, synthetic biology,
system biology and integrated-omics, various novel and effective derivatives
can be developed using in vivo and in vitro approaches.
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in native/heterologous hosts (Gomez-Escribano and Bibb,
2011; Chaudhary et al., 2013; Hwang et al., 2014). The
production profile can bemodulated by interrogation with media
optimization or medium component selection strategies (Jose
et al., 2013). The application of synthetic biological tools such
as construction of a complete genetic circuit or rewiring the
transcriptional or post-transcriptional regulation, play significant
role in production and overproduction strategies (Medema et al.,
2011;Wohlleben et al., 2012;Weber et al., 2015) (Figure 1B). The
optimization of bioprocessing and fermentation technology may
help in harnessing the maximum yield of the desired compound.
In addition, for compounds that are cryptic and not amenable to
production from native host, a stable chassis can be utilized as
heterologous host. The host can in turn be rationally engineered
for maximum production using synthetic biological platform.
Antoraz et al. (2015) illustrated that diverse synthetic
biological approaches can be efficient method for precise
modifications to attain a newmolecules with better antimicrobial
activities. These synthetic biological techniques in synergy with
system biological impetus can be employed in two categories (a)
living cell based (in vivo) or (b) chemical reagents based (in vitro)
techniques (Figure 1C). The generation of natural product-
derived libraries is assisted by synthetic chemistry, where
novel structural diversity is generated by precursor directed
biosynthesis or mutasynthesis or semi-synthesis approaches
(Kirschning et al., 2007; Kennedy, 2008). In precursor-directed
biosynthesis, the synthetic analogs of some scaffold moieties
are fed and incorporated during metabolite production in
wild type strains generating novel analogs. Mutasynthesis is
a refined version of precursor directed biogenesis, where
the producer strain is engineered curtailing the competitive
pathways, yielding maximum production of desired compounds.
In semi-synthesis, the designed chemical moiety is attached to
the natural product by specific chemical reactions. In another
approach termed “combinatorial biosynthesis,” the substrate
promiscuity of natural or engineered enzymes and modulated
pathways is utilized to produce “unnatural products” with
potential pharmaceutical value (Sun et al., 2015). This approach
can be employed by altering the precursors or enzyme level
modifications through mutations. The domain alterations or
complete pathway level recombination is another approach for
combinatorial biosynthesis. In addition, the whole cell based in
vivo biotransformation or reaction tube based in vitro catalysis
contribute for generation of a repertoire of novel derivatives of
existing antimicrobials (Figure 1C).
It seems we are running out our defensive options due to
alarming increase in the drug resistant bug in contrast to decrease
in the introduction of new antimicrobials. There is skepticism
regarding potential post-antibiotic era when common infections
may lead to mortality because of dwindling antibiotic arsenal.
Antoraz et al. (2015) have illustrated the profound potential of
S. arsenal as prolific source of antibiotics and drug discovery.
Moreover, there are sufficiently availed details of biochemistry
and physiology behind the pathogenicity of resistant bacteria
as well as the biosynthetic ability of antimicrobial producers.
Hence, it can be hoped that more efficacious antimicrobials can
be developed from Streptomyces on the bases of all the available
knowledge resources and technologies.
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